Company intelligence / Profile preview

Cellsonics

San Jose, California, United Statescellsonics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cellsonics has developed the SimpleFlow system, a device that uses acoustic waves to dissociate tissues into single-cell suspensions. This method preserves cell populations and gene expression profiles better than enzymatic methods, making it suitable for applications such as flow cytometry and single-cell RNA sequencing. The company’s data show improved preservation of astrocytes and neurons compared to traditional enzyme-based dissociation. No clinical results are relevant as this is a research tool.

Modalities: DeviceNon-pharmacological therapy (ultrasound-based tissue dissociation)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Cellsonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellsonics.

Explore the full profile